MediWound Ltd. (NASDAQ:MDWD) Given Average Rating of "Hold" by Analysts

Key Points

• Analyst sentiment is mixed: Five analysts give MediWound an average “Hold” rating, with three buys, one hold and one sell. The average 12-month price target is $33.00, well above the recently reported share price of $13.52.
• MediWound reported a quarterly loss of $0.77 per share, narrowly missing expectations, while revenue of $3.09 million exceeded the $2.59 million consensus estimate. The company continues to report substantial negative profitability metrics.
• The stock has declined from its 12-month high of $20.03 and trades near its 12-month low of $12.52; institutional investors own approximately 46.83% of outstanding shares, while a company COO recently sold shares worth about $51,000.

Shares of MediWound Ltd. (NASDAQ:MDWD - Get Free Report) have earned an average recommendation of "Hold" from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $33.00.

Several equities analysts have weighed in on MDWD shares. Weiss Ratings lowered MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, September 8th. Alliance Global Partners reiterated a "buy" rating on shares of MediWound in a research note on Wednesday. Wall Street Zen lowered shares of MediWound from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th. Finally, Oppenheimer reissued an "outperform" rating and set a $30.00 price target (down from $32.00) on shares of MediWound in a research note on Friday, August 14th.

MediWound Price Performance

Shares of NASDAQ MDWD traded up $0.05 during midday trading on Wednesday, reaching $13.52. The company's stock had a trading volume of 12,461 shares, compared to its average volume of 94,720. The stock has a market capitalization of $173.73 million, a P/E ratio of -7.51 and a beta of 0.14. The firm has a 50 day moving average price of $13.80 and a 200-day moving average price of $15.27. MediWound has a 12-month low of $12.52 and a 12-month high of $20.03.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The business had revenue of $3.09 million for the quarter, compared to analysts' expectations of $2.59 million. On average, equities analysts predict that MediWound will post -2.31 EPS for the current year.

Insider Transactions at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a filing with the SEC, which is available at this link. 9.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On MediWound

A number of large investors have recently bought and sold shares of the stock. UBS Group AG grew its holdings in shares of MediWound by 90.1% in the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company's stock worth $2,678,000 after purchasing an additional 68,756 shares during the last quarter. Silverberg Bernstein Capital Management LLC raised its holdings in MediWound by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company's stock valued at $3,222,000 after buying an additional 16,081 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd boosted its position in MediWound by 22.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 71,000 shares of the biopharmaceutical company's stock valued at $1,311,000 after buying an additional 13,196 shares during the period. 46.83% of the stock is owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company's products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound's lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.